Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01487
|
|||||
Drug Name |
4-Hydroxytamoxifen
|
|||||
Synonyms |
4-Hydroxytamoxifen; Afimoxifene; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Breast cancer [ICD11: 2C60-2C6Z] | Phase 3 | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C26H29NO2
|
|||||
Canonical SMILES |
CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
|
|||||
InChI |
InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
|
|||||
InChIKey |
TXUZVZSFRXZGTL-QPLCGJKRSA-N
|
|||||
CAS Number |
CAS 68047-06-3
|
|||||
Pharmaceutical Properties | Molecular Weight | 387.5 | Topological Polar Surface Area | 32.7 | ||
Heavy Atom Count | 29 | Rotatable Bond Count | 8 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
XLogP |
6.8
|
|||||
PubChem CID | ||||||
PubChem SID |
7494
, 835333
, 7889566
, 10300358
, 11532960
, 14719814
, 14719815
, 14805025
, 24895736
, 24895814
, 24899989
, 26757818
, 26759601
, 36891034
, 46393897
, 47208207
, 48243335
, 49688682
, 49846252
, 50005439
, 50065066
, 53788270
, 53789854
, 56422185
, 57404921
, 57570889
, 57654657
, 77095723
, 85788533
, 87219226
, 91613892
, 93165645
, 93167122
, 103169566
, 104640983
, 124799764
, 124893066
, 126639485
, 126671492
, 126685161
, 134341205
, 135021191
, 135065359
, 135610264
, 137156415
, 142089319
, 144208141
, 162226886
, 163414603
, 163687254
|
|||||
ChEBI ID |
CHEBI:44616
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | ClinicalTrials.gov (NCT03199963) Trial of 4-OHT Gel in Women Aimed at Reducing Dense Breast Tissue | |||||
2 | Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.